Editorial Comment: Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an... read the full article here! 👉 bit.ly/4gfeB4A #AUA #Urology #AUAmembers #TheVoiceofUrology

Our editorial on the #BladderPath study: Could MRI-first staging streamline MIBC treatment? Skipping TURBT may reduce delays—especially for those needing palliative care or radiotherapy. Journal of Clinical Oncology Andrea Necchi jim catto Nick James also on @Prof-Nick-James.bsky.social #OncSurgery #BladderCancer

Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response on long-term outcomes from #NIAGARA. Perioperative durvalumab + chemo in #MIBC shows: ✅ 33% ↓ risk of metastasis/death (HR 0.67) ✅ 31% ↓ risk of bladder

Our meta-analysis of two RCTs shows that extended LND does not improve RFS or OS compared to standard LND but leads to higher morbidity in bladder cancer patients undergoing RC Marco Moschini Benjamin Pradere World Journal of Urology

Real-world data on nadofarogene firadenovec for BCG-unresponsive #BladderCancer. Mark Tyson Mayo Clinic & Jacob Moyer join Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to share real-world data on nadofarogene firadenovec in BCG-unresponsive #NMIBC, showing 79% CR in CIS & 68% in papillary-only

Our new SR and MA published in European Urology Oncology evaluates focal therapy for localized PCa using prospective data only. Important for patient counselling. 📊 50 studies, 4,615 patients 📊 12-mo csPCa RFS in intermediate-risk: 79% (95% CI 74–83%) 🔗 doi.org/10.1016/j.euo.…

Our meta-analysis of 50 prospective studies demonstrates promising short-term oncological outcomes of focal therapy in clinically localized PCa and a favorable safety profile. European Urology Oncology

Bladder preservation in muscle-invasive bladder cancer (MIBC) is evidence-based, patient-centered, and underutilized The latest IBCG consensus in European Urology offers global expert recommendations on when, how, and for whom bladder-sparing strategies are appropriate

Radical cystectomy vs bladder-sparing therapy for recurrent high-grade non-muscle invasive bladder cancer: Results from the comparison of intravesical therapy and surgery as treatment. The #CISTO study. Presented by John Gore, MD, MS, FACS University of Washington. #AUA25 written coverage by

Review – Bladder Cancer: The Financial Burden of Localized and Metastatic Bladder Cancer by Pietro Scilipoti, Marco Moschini et al Read the full article here: buff.ly/44pcBYA #UroSoMe #MedTwitter #EurUrol #BladderCancer

📣 Very High-risk NMIBC: real-world data challenge guidelines on upfront radical cystectomy. Happy to share our European Urology editorial Thanks Ashish M. Kamat, MD, MBBS, Roberto Contieri , Renate Pichler , #PietroScilipoti, Niyati Lobo for your support 🙏 #BladderCancer #Urology #Oncology

Simple pre-op factors can reliably predict kidney function 1 year after partial nephrectomy for RCC. 🔍 Linear regression performed as well as advanced machine-learning models. 📊 Predictors: baseline GFR, tumor size, comorbidities. mdpi.com/3309276 Cancers MDPI

Dziękuję FNP Foundation for Polish Science za przyznanie stypendium START! To dla mnie ogromne wyróżnienie i motywacja do dalszej pracy badawczej! #JestemStartowcem #MłodaPolskaNauka #FNP

Our team is in Sevilla for #UROonco25 📩 #NMIBC Deintensify LG Biomarkers to ⬇️ cystoscopy in HG #MIBC ctDNA is the future #UTUC Tailored patient care Go for kidney-sparing treatment European Association of Urology (EAU) EAU Edu Platform UROONCO EAU Young Academics

Thank you for the opportunity to speak at UROonco25 during the Best of Onco-Urology Journals session! EAU Edu Platform UROONCO Alessandro Volpe Morgan Roupret EAU YAU Urothelial Carcinoma

Our SEER-based study shows that pts with cN+ M0 bladder cancer who received chemotherapy + radical cystectomy had better CSS and OS compared to those who had chemoradiation. The 5-yr OS was only 25%. sciencedirect.com/science/articl… Pietro Scilipoti Marco Moschini Benjamin Pradere Stephen Boorjian, MD

🚨Online now: TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in muscle-invasive #bladdercancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a phase 2 trial thelancet.com/journals/lanon…

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery